TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

As of the latest trading close, TGTX, a Healthcare sector stock, is trading -3.15% below its 52-week high but remains 285.29% above its 52-week low. The Average True Range (ATR) (14 days) of 1.42 ...

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

Check the time stamp on this data. Updated AI-Generated Signals for Tg Therapeutics Inc. (TGTX) available here: TGTX.

The data showed that continued use of BRIUMVI resulted in an annualized relapse rate of 2% at year five. TG Therapeutics, Inc. TGTX stock is trading higher on Wednesday after the company announced it ...

Investors in TG Therapeutics Inc (Symbol: TGTX) saw new options begin trading today, for the November 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

TG Therapeutics, Inc. TGTX stock is trading higher on Wednesday after the company announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials ...

TG Therapeutics (TGTX) In a report released yesterday ... In a report issued on September 4, Raymond James also maintained a Buy rating on the stock with a $94.00 price target. Boston Scientific ...